

WD
#8
Amst. A
w/seq.
List
11/8/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/856,086
Filing Date: July 30, 2001
Applicant: EBRINGER, ALAN

Attorney Docket No.: 78104.040
Group Art Unit: 1648
Examiner: Scheiner, Laurie A.

Title: **DIAGNOSIS OF DEMYELINATING OR SPONGIFORM DISEASE**

**TRANSMITTAL OF COMPUTER READABLE COPY
OF SEQUENCE LIST**

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1803
Arlington, VA 22202

RECEIVED

OCT 31 2002

TECH CENTER 1600/2900

RECEIVED
TECH CENTER 1600/2900
02 OCT 29 PM 3:14

To the Commissioner:

*Seq. List
placed
before*

In response to the Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures which was mailed on October 2, 2002, enclosed are the following documents for filing with the above-referenced U.S. Patent Application:


- 1) Statement that the content of the paper copy of the "Sequence Listing" and the "Sequence Listing" in computer readable form are the same as required by 37 C.F.R. 1.821(g).
- 2) Sequence List in computer readable format and paper copy
- 3) Copy of Notice to Comply With Requirements For Patent Applications Containing Nucelotide Sequence and/or Amino Acid Sequence Disclosures
- 4) Preliminary Amendment

APPLICANTS REQUEST THAT THE PREVIOUSLY SUBMITTED SEQUENCE LIST BE DELETED AND THE SUBSTITUTE SEQUENCE LIST ATTACHED HERETO BE ENTERED IN ITS PLACE.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 18-2055.

Having now complied with all of the requirements of 37 C.F.R. §§1.81-1.825, applicants respectfully request that this application be placed upon the files for examination.

Respectfully submitted,


Joseph T. Leone, Reg. No. 37,170
DEWITT ROSS & STEVENS S.C.
8000 Excelsior Drive, Suite 401
Madison, Wisconsin 53717-1914
Telephone: (608) 831-2100
Facsimile: (608) 831-2106

I hereby certify that this correspondence is being sent via Federal Express in an envelope addressed to:

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Date of Deposit: 10-28-02

Federal Express No.: 7906 1877 0788

Signature: Morris Layton

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-308-6900

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE